K36 Therapeutics Named “Overall BioPharma Startup of the Year” By BioTech Breakthrough
November 08, 2023 08:05 ET
|
BioTech Breakthrough
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- K36 Therapeutics (“K36”) has been selected as “Overall BioPharma Startup of the Year” in the third annual BioTech Breakthrough Awards Program...
Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
December 16, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today further progress on developing Ampligen® (rintatolimod)...
MolecularMD Corp. Obtains Exclusive License to LKB1 Uses in Non-Small Cell Lung Cancer
January 28, 2013 08:30 ET
|
MolecularMD
PORTLAND, OR--(Marketwire - Jan 28, 2013) - MolecularMD Corp. announced today that it has entered into a license agreement granting the company exclusive patent rights to cancer diagnosis...